Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
- Drug Discovery
- Disease Autoimmune
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 289928
ONS-3010 is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohnâ€™s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.
Humira, the reference product for ONS-3010, is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohnâ€™s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.
IPSCIO Record ID: 372447
Antigen shall mean Tumor Necrosis Factor alpha.
Licensed Product shall mean any product containing an Antibody related to this agreement.
U.S. patents are commonly known as the â€œCabillyâ€ patents. The Cabilly patents cover key steps of therapeutic antibody manufacturing methods. One of the Cabilly patent covers a process for producing an immunoglobulin molecule (Ig) in a single host cell; the second Cabilly patent covers a method for making an antibody heavy chain and antibody light chain in a recombinant host cell.
Tumor necrosis factor, or TNF, belongs to a family of soluble protein mediators, or cytokines, that play an important role in disease progression across a number of inflammatory and chronic conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohnâ€™s Disease, psoriasis and ulcerative colitis. Cytokines, such as TNF, are substances produced by cells in the body that can cause a biological effect on other cells in the body. TNF is generally understood as the â€œmaster regulatorâ€ of the bodyâ€™s immune response and is the key initiator of immune-mediated inflammation in multiple organ systems. Several biologic agents have been developed that inhibit the inflammatory activity of TNF in the context of these diseases, which are collectively referred to as the anti-TNF class of therapeutics.
IPSCIO Record ID: 385928
Licensee hereby grants to Licensor a limited, revocable, non-exclusive, royalty free, non-transferable license (without the right to sublicense) to use the Licensee Marks and the Product Marks during the Product Terms solely for the purposes of packaging, labeling and branding the Products to be supplied to Licensee in accordance with the Packaging Specifications. Licensor acknowledges and agrees that Licensee is the sole and exclusive owner of all right, title and interest in and to the Licensee Marks and the Product Marks. All goodwill associated with the Licensee Marks and the Product Marks shall inure to the benefit of Licensee.
Licensor shall manufacture for, and sell and deliver to, Licensee its total requirements for the applicable Product for sale, or resale by its Affiliates and Third Parties (including Distributors) in the Licensee Territories
Licensor shall (i) use commercially reasonable efforts to develop such Product for the uses of such Product set forth in the Product Data Sheet for such Product in accordance with the Research Plan and (ii) use commercially reasonable efforts (taking into account the commercial potential of such Product in each Licensee Territory) to obtain, in its own name (or the name of one of its Affiliates) and at its own cost, Regulatory Approvals for such Product in the Licensee Territories. Licensor shall use commercially reasonable efforts to conduct the Research Program in good scientific manner and using cGxP of the applicable Territory or other applicable jurisdiction where the Research Program is being conducted, to achieve the objectives of the Research Program efficiently and expeditiously, in compliance with all Applicable Laws. Licensor shall complete all Phase 4 and post-marketing surveillance studies required to be completed by any Regulatory Agency with respect to a Product as a condition to Regulatory Approval of such Product.
Initial Products means the Adalimumab Product, the Denosumab Product, the Golimumab Product, and the Ustekinumab Product.
Biosimilar means, as compared to the reference product of a Product, a biologic product consisting of a protein or peptide targeting one or more of the same indications as such reference product and that does not differ in any clinically meaningful way from such reference product with respect to its amino acid sequence, analytical comparability, safety or efficacy.
Denosumab is a human monoclonal antibody for the treatment of osteoporosis and hypercalcemia. It can also treat bone cancer and bone problems in patients who have cancer.
Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication use to treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Ustekinumab is a monoclonal antibody medication for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.
IPSCIO Record ID: 26092
Humira (adalimumab) is a fully human anti-TNFa monoclonal antibody, isolated and optimized by Licensor in collaboration with Licensee and now approved for marketing as a treatment for rheumatoid arthritis or RA, early RA and Psoriatic arthritis. Humira (adalimumab) is Licensor's only marketed product, approved as a rheumatoid arthritis treatment.
IPSCIO Record ID: 289246
Licensor has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies that are highly potent compared with Remicade and Humira in in-vitro assays.
Licensor will provide Humanized Rabbit anti-TNFalpha monoclonal antibodies to Licensee.
IPSCIO Record ID: 289253
Tumor necrosis factor a (TNF) is one of the key chemical messengers that help regulate the inflammatory process and plays an important role in the underlying mechanisms of conditions such as rheumatoid arthritis, psoriasis, and many other inflammatory disorders. When the body produces too much TNF, it overwhelms the immune systemâ€™s ability to control inflammation of the joints or of psoriasis-affected skin areas. The TNF inhibitors are molecules that disrupt the TNF function by blocking the binding of TNF to the TNF receptors. Blockage of these receptors can result in a significant reduction in inflammatory activity and reduce symptoms, inhibit the progression of structural damage, and improve physical function in patients with moderate to severe rheumatoid arthritis.
IPSCIO Record ID: 341530
Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.
Crohnâ€™s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.
Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).
Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.
Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.
IPSCIO Record ID: 314
The Licensor also granted the Licensee an exclusive worldwide License (including the right to sublicense) to its interest in the Joint Intellectual Property and its know-how related to the Project and the right to commercialize products that, without the Licenses granted under the JOELA, would infringe the Licensed IP.
The Licensor retains the non-exclusive and non-transferable right to use the Licensed IP for its own internal, academic purposes.
TSO, or CNDO-201, is a biologic comprising Trichuris suis ova, the microscopic eggs of the porcine whipworm, which we believe could be used for the treatment of a range of autoimmune diseases, such as Crohnâ€™s disease, or Crohnâ€™s, ulcerative colitis, or UC, multiple sclerosis, or MS, autism, psoriasis, Type 1 diabetes, or T1D, psoriatic arthritis and rheumatoid arthritis.
In February 2012, the licensee announced positive results from a Phase 1 clinical trial of TSO in 36 patients with Crohnâ€™s. The trial was a sequential dose-escalation, double-blind, placebo-controlled study to examine safety and tolerability. TSO was shown to be safe and well tolerated, with no serious treatment-related adverse events reported. To date, a number of investigator-sponsored clinical trials have been conducted using TSO in patients suffering from Crohnâ€™s, UC or MS. These studies also demonstrated that TSO is safe and well tolerated.
IPSCIO Record ID: 66786